Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Botulinum Toxins, Type A: later-stage trial registry

1 of 1 indexed Botulinum Toxins, Type A trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Botulinum Toxins, Type A: 1 US clinical trial tracked, 1 recruiting.

Botulinum Toxins, Type A is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Merz North America, running 1 of these trials.

Enrollment posture brief

Registry condition botulinum-toxins-type-a

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Botulinum Toxins, Type A (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Botulinum Toxins, Type A

Botulinum Toxins, Type A lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Botulinum Toxins, Type A on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Botulinum Toxins, Type A is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Botulinum Toxins, Type A records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

NT 201 Placebo Drug
1 trials
NT 201 Drug
1 trials

US sites by state

Facility locations filed on Botulinum Toxins, Type A trials. A trial with sites in several states counts in each.

New York 1 trials
Maryland 1 trials
Illinois 1 trials
Georgia 1 trials
Florida 1 trials
Connecticut 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Botulinum Toxins, Type A page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Botulinum Toxins, Type A trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Merz North America sponsors the most Botulinum Toxins, Type A trials on record, review their full trial history before evaluating a specific study. See Merz North America's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Botulinum Toxins, Type A condition card totals 1 registered trials; most-linked intervention NT 201 Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.